Bristol -Myers Squibb News
Bristol -Myers Squibb News
Bristol-Myers Squibb and Exelixis reveal trial results
Bristol-Myers Squibb and Exelixis reveal trial results
Zenopa - 3 minutes ago
Bristol-Myers Squibb, working in cooperation with Exelixis, has announced the outcome of a study into XL184. The treatment is being tested to treat patients with glioblastoma multiforme (GBM ...
Sanofi-Aventis to Create China Vitamin JV with Minsheng
Sanofi-Aventis to Create China Vitamin JV with Minsheng
istockAnalyst.com - 46 minutes ago
signed a letter of intent last Saturday to establish a joint venture with Minsheng Pharmaceutical Group of Hangzhou. The JV will focus on OTC vitamin and mineral products. Minsheng already ...
Bristol-Myers Q3 net income up
Bristol-Myers Q3 net income up
Trading Markets - 7 hours ago
Oct 26, 2009 (Datamonitor via COMTEX) -- BMY -- Bristol-Myers Squibb Company has reported a net income attributable to the company of $966 million, or $0.48 per diluted share, for the third ...
Looking for a New Job? Follow the Pink Slips
Looking for a New Job? Follow the Pink Slips
Smartmoney.com - 18 minutes ago
Bristol-Myers Squibb (BMY) intends to lay off 113 full-time employees at its facilities in Evansville and Mount Vernon, Ind. Sun Microsystems (JAVA) plans to eliminate 3,000 positions world-wide ...
Market Report -- In Play (EXEL)
Market Report -- In Play (EXEL)
MSN Money - 1 hour ago
Exelixis and Bristol-Myers report new Ph. 2 data for XL184 in patients with glioblastoma multiforme Co and Bristol-Myers Squibb (BMY) report updated phase 2 clinical data which show that XL184 ...
Medidata Solutions Signs Contract Extension with Bristol-Myers Squibb
Medidata Solutions Signs Contract Extension with Bristol-Myers Squibb
Trading Markets - 47 minutes ago
Oct 26, 2009 (Close-Up Media via COMTEX) -- MDSO -- Medidata Solutions, a provider of hosted clinical development solutions, announced a multi-year contract extension with Bristol-Myers Squibb ...
Exelixis, Inc. And Bristol-Myers Squibb Co. Report New Phase 2 Data For XL184 in Patients With Common And Aggressive Form Of Brain Cancer
Exelixis, Inc. And Bristol-Myers Squibb Co. Report New Phase 2 Data For XL184 in Patients With Common And Aggressive Form Of Brain Cancer
Reuters Key Development - 1 hour ago
